IP Library Granted Patent US 11,274,102
Granted Patent B2
US 11,274,102 · App. 16/758,085 · Granted Mar 15, 2022

Compounds useful in HIV therapy

Inventors: David Favre (Research Triangle Park, NC); Robert G. Ferris (Research Triangle Park, NC); Jun Tang (Research Triangle Park, NC)
Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
C07D491/048A61K9/16A61K9/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,274,102
App. No.
16/758,085
Granted
Mar 15, 2022
Kind
B2
Abstract

The invention relates to compounds of Formula (I), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.

Claims (37)

1. A compound of the formula (I):

wherein:

Y 1 is a 5- or 6-membered aryl or heteroaryl optionally substituted by one or more substituents independently selected from the group consisting of chloro, fluoro, oxo, and alkoxy;

R 1 is C 1 -C 6 alkylene; and

Y 2 is a ring of the formula:

wherein R 2 is selected from the group consisting of -chloro, fluoro, oxo and alkoxy;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein Y 1 is an aryl.

3. The compound according to claim 2 , wherein Y 1 is an aryl substituted by Cl.

4. The compound according to claim 3 , wherein Y 1 is of the formula:

5. The compound according to claim 1 , wherein Y1 is a 5-membered heteroaryl.

6. The compound according to claim 5 , wherein the 5-membered heteroaryl contains at least one heteroatom which is O or S.

7. The compound according to claim 1 , wherein R 1 is C 1 alkyl.

8. The compound according to claim 1 , wherein R 1 is C 2 alkyl.

9. The compound according to claim 1 , selected from the group consisting of:

Parent Structure

Chemical Name

1-((5-((5-(4-chlorophenyl)furo[2,3- d]pyrimidin-4-yl)thio)-1,3,4-oxadiazol- 2-yl)methyl)pyrrolidin-2-one

1-((5-((5-(4-chlorophenyl)furo[2,3- d]pyrimidin-4-yl)thio)-1,3,4-oxadiazol- 2-yl)methyl)pyrrolidin-2-one

1-((5-((5-(4-chlorophenyl) furo[2,3-d]pyrimidin-4-yl)thio)- 1,3,4-oxadiazol-2-yl) methyl)pyrrolidin-2-one

1-((5-((5-(furan-2-yl)furo[2,3- d]pyrimidin-4-yl)thio)-1,3,4-oxadiazol- 2-yl)methyl)pyrrolidin-2-one

1-((5-((5-(furan-2-yl)furo[2,3- d]pyrimidin-4-yl)thio)-1,3,4-oxadiazol- 2-yl)methyl)pyrrolidin-2-one

1-((5-((5-(thiophen-2-yl)furo[2,3- d]pyrimidin-4-yl)thio)-1,3,4- oxadiazol-2-yl)methyl)pyrrolidin-2- one

1-((5-((5-(5-methylthiophen-2- yl)furo[2,3-d]pyrimidin-4-yl)thio)-1,3,4- oxadiazol-2-yl)methyl)pyrrolidin-2-one

and a pharmaceutically acceptable salt thereof.

10. A compound of the formula (II):

wherein R 1 is C 1 -C 6 alkyl; and

R 3 is hydrogen, oxo, chloro or fluoro.

11. A compound of the formula (III):

or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

13. The composition of claim 12 , wherein the compound is present in an amorphous form.

14. The composition of claim 12 , wherein the composition is in a tablet form.

15. The composition of claim 12 , wherein the compound is present as a spray dried dispersion.

16. A method of curing an HIV infection in a subject comprising administering to the subject a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

17. A method of treating an HIV infection in a subject comprising administering to the subject a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

18. A method of preventing an HIV infection in a subject at risk for developing an HIV infection, comprising administering to the subject a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (2)
CHANGE OF ADDRESS Recorded Oct 8, 2025
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 073032/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2022
From: FAVRE, DAVID; FERRIS, ROBERT G.; TANG, JUN
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 058840/0456 →
Continuity (2)
Provisional Application 62578576 · Oct 30, 2017
Related Publication 20200325147A1 · Oct 15, 2020